Researchers at Florida's Moffitt Cancer Center are gaining deeper insight into the biological processes going on inside a tumor in an effort to battle cancer more effectively. They've developed a new technique to analyze specific protein complexes in cancer specimens.
Philips announced that it will offer Indica Lab's Halo image analysis software platform with its Digital Pathology Solutions products to enable enhanced analysis of cancerous tissue samples. The upgraded product offering is for research use only, meaning it won't be used to make clinical decisions affecting individual patients.
Famed biotech entrepreneur Dr. Patrick Soon-Shiong opted to unveil core details on his patient monitoring company NantHealth at this week's JP Morgan Healthcare conference. The private company has already spent $1.5 billion in the past decade to enable patient monitoring and real-time data analysis that examines the patient experience in the hospital and at home via connected medical devices, as well as to cost and outcomes data that's available via mobile devices.
Researchers have developed graphene strips that have demonstrated the ability to carry two different cancer drugs and target each to the part of the cell where it will be most effective. The surface area of a flat strip in particular suits these particles to the delivery of the cancer drugs TRAIL and doxorubicin.
Cerulean Pharma announced last week that the first patient has received its Phase I/IIa cancer candidate, CRLX301, delivered using its RNA-based Dynamic Tumor Targeting Platform.
AstraZeneca won accelerated FDA approval for its ovarian cancer fighter Lynparza (olaparib), opening the door for potential blockbuster sales of the drug and helping the company distinguish itself from rivals in the BRCA playing field.
Researchers at Harvard University have demonstrated that a nonsurgical injection of programmable biomaterial can assemble in vivo into a 3-D structure to attack cancer cells and help to prevent other infectious diseases such as HIV.
Combining diagnostics and drug delivery is an ideal progression to improve the effectiveness and speed of treatment and a way to make drugs "smarter." To make one of these two-in-one systems, Singapore-based researchers developed a new biomarker that lights up to locate tumors and releases cancer drugs at the same time.
Rising cancer drug prices aren't just alarming to payers. They're squeezing oncologists, too, at a time when doctors are paid less to administer drugs--to the point where they're selling out to hospitals.
The only FDA-approved, wearable cancer treatment device may expand its reach. A Phase III trial of Optune (NovoTTF-100A System) from Novocure was halted early due to statistically significant efficacy for the device in combination with chemotherapy to treat newly diagnosed glioblastoma patients.